Clinical Trial Update: Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating abiraterone acetate with docetaxel after progression to abiraterone in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED